Table 1.
2020 (Feb–Jun) (n = 169) |
2017–19 (Feb–Jun) (n = 443) |
P value | |
---|---|---|---|
Age at diagnosis, mean ± SD | 69.4 ± 11.1 | 69.0 ± 10.6 | 0.637 |
Sex, Female | 53 (31.4%) | 135 (30.5%) | 0.832 |
Performance, ECOG 0–2, (%) | 91.7% | 93.2% | 0.686 |
Smoking, never smoker, (%) | 34.4% | 29.3% | 0.443 |
Subtype | 0.807 | ||
NSCLC | 146 (86.4%) | 386 (87.1%) | |
SCLC | 23 (13.6%) | 57 (12.9%) | |
Stage of NSCLC | 0.015* | ||
IA–IB | 31 (21.2%) | 98 (25.4%) | |
IIA–IIB | 6 (4.1%) | 47 (12.2%) | |
IIIA–IIIC | 28 (19.2%) | 76 (19.7%) | |
IVA–IVB | 81 (55.5%) | 165 (42.7%) | |
Stage of SCLC | 0.042 | ||
Limited disease | 11 (47.8%) | 14 (24.6%) | |
Extensive disease | 12 (52.2%) | 43 (75.4%) |
SD standard deviation, ECOG Eastern Cooperative Oncology Group, NSCLC non-small cell lung cancer, SCLC small cell lung cancer
*Statistical significance was tested by the linear by linear association